Pfizer Announces Executive and Board Changes
Ticker: PFE · Form: 8-K · Filed: Jul 26, 2024 · CIK: 78003
| Field | Detail |
|---|---|
| Company | Pfizer Inc (PFE) |
| Form Type | 8-K |
| Filed Date | Jul 26, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-changes, board-appointment, leadership-transition
Related Tickers: PFE
TL;DR
Pfizer's CSO is stepping down, new CSO appointed, and a new board member joins. Big pharma shuffle.
AI Summary
On July 24, 2024, Pfizer Inc. announced changes in its executive leadership and board of directors. Dr. Mikael Dolsten will transition from his role as Chief Scientific Officer to a Senior Advisor role, effective August 1, 2024, and will be succeeded by Dr. Arpa S. Garber. Additionally, Mr. Ronald A. Rittenmeyer Jr. has been appointed to the Board of Directors.
Why It Matters
These leadership transitions and board appointments could signal shifts in Pfizer's strategic direction and scientific focus, potentially impacting its future drug development and market performance.
Risk Assessment
Risk Level: medium — Leadership changes and board appointments can introduce uncertainty regarding future strategy and execution, impacting investor confidence.
Key Players & Entities
- Pfizer Inc. (company) — Registrant
- Dr. Mikael Dolsten (person) — Chief Scientific Officer transitioning to Senior Advisor
- August 1, 2024 (date) — Effective date of Dr. Dolsten's transition
- Dr. Arpa S. Garber (person) — New Chief Scientific Officer
- Mr. Ronald A. Rittenmeyer Jr. (person) — Appointed to the Board of Directors
- July 24, 2024 (date) — Date of the earliest event reported
FAQ
Who is succeeding Dr. Mikael Dolsten as Chief Scientific Officer?
Dr. Arpa S. Garber is succeeding Dr. Mikael Dolsten as Chief Scientific Officer.
When is Dr. Mikael Dolsten's transition to Senior Advisor effective?
Dr. Mikael Dolsten's transition to Senior Advisor is effective August 1, 2024.
Has Pfizer appointed any new members to its Board of Directors?
Yes, Mr. Ronald A. Rittenmeyer Jr. has been appointed to the Board of Directors.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is July 24, 2024.
What is Pfizer Inc.'s principal executive office address?
Pfizer Inc.'s principal executive office is located at 66 Hudson Boulevard East, New York, New York 10001-2192.
Filing Stats: 1,497 words · 6 min read · ~5 pages · Grade level 13.2 · Accepted 2024-07-26 11:09:20
Filing Documents
- pfe-20240724.htm (8-K) — 43KB
- tsruex991.htm (EX-99.1) — 8KB
- psasex9922.htm (EX-99.2) — 10KB
- pfizerlogo7-25.jpg (GRAPHIC) — 11KB
- pfizerlogo7-251.jpg (GRAPHIC) — 11KB
- 0000078003-24-000144.txt ( ) — 261KB
- pfe-20240724.xsd (EX-101.SCH) — 3KB
- pfe-20240724_def.xml (EX-101.DEF) — 15KB
- pfe-20240724_lab.xml (EX-101.LAB) — 27KB
- pfe-20240724_pre.xml (EX-101.PRE) — 16KB
- pfe-20240724_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events Modifications to Five-Year Total Shareholder Return Units and Performance Share Awards In order to retain key colleagues critical to the success of our business and ensure focus on long-term performance by linking their compensation to our total shareholder return, on July 24, 2024, the Compensation Committee (the Committee) of our Board of Directors approved modifications to outstanding Five-Year Total Shareholder Return Units (TSRUs) and Performance Share Awards (PSAs) granted in 2022 and 2023 to eligible active participants. The modifications will affect up to 9,000 active employees holding at least one of these grants, including the following named executive officers – Albert Bourla, David M. Denton, Mikael Dolsten, Aamir Malik, Angela Hwang and Douglas M. Lankler. Current outstanding TSRUs represent an important retention tool while aligning the interests of participants with shareholders by providing value tied to absolute total shareholder return. The Committee approved modifications to the Five-Year TSRUs granted to eligible participants in 2022 and 2023 to provide those participants the ability to elect to extend their respective terms by two additional years. If such an election is made, the settlement period for Five-Year TSRUs granted in 2022 will end in February 2029 rather than 2027, and the settlement period for Five-Year TSRUs granted in 2023 will end in February 2030 rather than 2028. In addition, the vesting period will be extended by two years so that these 2022 and 2023 TSRUs will now vest on the fifth anniversary of the grant date instead of the third anniversary. Further, the treatment of TSRUs in the event of a holder's death will be updated, to provide for settlement based on the greater of binomial value or intrinsic value, which is consistent with the terms provided in the 2024 grants. All other terms of the 2022 and 2023 Five-Year TSRUs will remain unchanged. Current outstanding PSAs align rewards to both a st
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit Description Exhibit 99.1 Email Announcement to Eligible Participants: Important Information Regarding Long-Term Incentive (TSRUs) Exhibit 99..2 Email Announcement to Eligible Participants: Important Information Regarding Long-Term Incentive (PSAs) 104 Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PFIZER INC. Dated: July 26, 2024 By: /s/ Margaret M. Madden Margaret M. Madden Senior Vice President and Corporate Secretary Chief Governance Counsel